Logo image of ABOS

ACUMEN PHARMACEUTICALS INC (ABOS) Stock Fundamental Analysis

NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD

1.39  +0.01 (+0.72%)

After market: 1.39 0 (0%)

Fundamental Rating

1

Overall ABOS gets a fundamental rating of 1 out of 10. We evaluated ABOS against 571 industry peers in the Biotechnology industry. The financial health of ABOS is average, but there are quite some concerns on its profitability. ABOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABOS has reported negative net income.
ABOS had a negative operating cash flow in the past year.
In the past 5 years ABOS always reported negative net income.
ABOS had a negative operating cash flow in each of the past 5 years.
ABOS Yearly Net Income VS EBIT VS OCF VS FCFABOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

ABOS has a Return On Assets of -30.59%. This is in the better half of the industry: ABOS outperforms 67.02% of its industry peers.
ABOS's Return On Equity of -37.60% is fine compared to the rest of the industry. ABOS outperforms 72.91% of its industry peers.
Industry RankSector Rank
ROA -30.59%
ROE -37.6%
ROIC N/A
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
ABOS Yearly ROA, ROE, ROICABOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABOS Yearly Profit, Operating, Gross MarginsABOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ABOS has more shares outstanding
ABOS has a worse debt/assets ratio than last year.
ABOS Yearly Shares OutstandingABOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ABOS Yearly Total Debt VS Total AssetsABOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.81, we must say that ABOS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.81, ABOS is in line with its industry, outperforming 59.54% of the companies in the same industry.
ABOS has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.14, ABOS is doing worse than 68.81% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACCN/A
ABOS Yearly LT Debt VS Equity VS FCFABOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

ABOS has a Current Ratio of 10.43. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
ABOS has a Current ratio of 10.43. This is amongst the best in the industry. ABOS outperforms 81.46% of its industry peers.
A Quick Ratio of 10.43 indicates that ABOS has no problem at all paying its short term obligations.
ABOS has a better Quick ratio (10.43) than 81.46% of its industry peers.
Industry RankSector Rank
Current Ratio 10.43
Quick Ratio 10.43
ABOS Yearly Current Assets VS Current LiabilitesABOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

ABOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.32%.
EPS 1Y (TTM)-22.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -11.44% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-49.22%
EPS Next 2Y-32.47%
EPS Next 3Y-19.35%
EPS Next 5Y-11.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABOS Yearly Revenue VS EstimatesABOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABOS Yearly EPS VS EstimatesABOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABOS Price Earnings VS Forward Price EarningsABOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABOS Per share dataABOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

ABOS's earnings are expected to decrease with -19.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.47%
EPS Next 3Y-19.35%

More info and screens

0

5. Dividend

5.1 Amount

ABOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (2/21/2025, 8:00:00 PM)

After market: 1.39 0 (0%)

1.39

+0.01 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners75.55%
Inst Owner Change-83.03%
Ins Owners6.18%
Ins Owner Change7.96%
Market Cap83.51M
Analysts86.67
Price Target11.02 (692.81%)
Short Float %3.48%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.67%
Min EPS beat(2)-34.3%
Max EPS beat(2)-19.05%
EPS beat(4)1
Avg EPS beat(4)-13.3%
Min EPS beat(4)-34.3%
Max EPS beat(4)5.73%
EPS beat(8)4
Avg EPS beat(8)-2.9%
EPS beat(12)4
Avg EPS beat(12)-21.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-48.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS3.62
TBVpS3.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.59%
ROE -37.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.43
Quick Ratio 10.43
Altman-Z -0.81
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y-49.22%
EPS Next 2Y-32.47%
EPS Next 3Y-19.35%
EPS Next 5Y-11.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-63.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.26%
EBIT Next 3Y-25.65%
EBIT Next 5YN/A
FCF growth 1Y-142.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.98%
OCF growth 3YN/A
OCF growth 5YN/A